Clinical ophthalmology (Auckland, N.Z.)最新文献

筛选
英文 中文
AI-Assisted Screening for Diabetic Retinopathy and Fundus Abnormalities in a Large-Scale Physical Examination Population. 大规模体检人群中糖尿病视网膜病变和眼底异常的人工智能辅助筛查
Clinical ophthalmology (Auckland, N.Z.) Pub Date : 2025-08-22 eCollection Date: 2025-01-01 DOI: 10.2147/OPTH.S538020
Xiaoying Liang, Yali Bao, Yongyi Du, Ning Kong
{"title":"AI-Assisted Screening for Diabetic Retinopathy and Fundus Abnormalities in a Large-Scale Physical Examination Population.","authors":"Xiaoying Liang, Yali Bao, Yongyi Du, Ning Kong","doi":"10.2147/OPTH.S538020","DOIUrl":"10.2147/OPTH.S538020","url":null,"abstract":"<p><strong>Purpose: </strong>Due to the high incidence rate of eye diseases, various artificial intelligence (AI) screening systems for retinal eye disorders have been developed at present. This study aimed to evaluate the diagnostic performance and clinical value of an AI-assisted system for large-scale screening of diabetic retinopathy (DR) and other fundus abnormalities in a real-world physical examination population.</p><p><strong>Methods: </strong>This retrospective study analyzed 54,353 fundus examination records collected from the local hospital in 2020. An AI-assisted system was used to screen for DR and other retinal abnormalities. Manual interpretation was conducted to validate AI predictions, and data were stratified by comorbidities and systemic risk factors.</p><p><strong>Results: </strong>Approximately 25% of individuals tested positive for fundus lesions. The AI-assisted system demonstrated high diagnostic performance, with a negative predictive value ≥96% and a positive predictive value ≥90%. Common abnormalities detected included retinal vascular sclerosis, drusen, maculopathy, optic cup enlargement, and hemorrhage. Higher positive detection rates were observed in individuals with a history of diabetes, hypertension, high myopia, and other systemic conditions, with detection rates increasing with disease duration.</p><p><strong>Conclusion: </strong>AI-assisted screening offers an effective, scalable approach for early DR detection and can also identify systemic diseases with retinal manifestations. Integration of AI with big data platforms enables timely intervention, especially in underserved areas. Building a multi-institutional DR data platform may revolutionize retinal disease management and improve patient outcomes. This study supports the clinical application of AI in enhancing diagnostic efficiency and targeting high-risk populations for early intervention.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"2889-2900"},"PeriodicalIF":0.0,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12380004/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144982463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intraocular Pressure Equations Utilizing Aqueous Fluid Flow and Flow Facility in the Steady-State and Time-Dependent Domains. 利用稳态和时变域的水流体流动和流动设施的眼压方程。
Clinical ophthalmology (Auckland, N.Z.) Pub Date : 2025-08-22 eCollection Date: 2025-01-01 DOI: 10.2147/OPTH.S531475
Sean Mccafferty, John Berdahl
{"title":"Intraocular Pressure Equations Utilizing Aqueous Fluid Flow and Flow Facility in the Steady-State and Time-Dependent Domains.","authors":"Sean Mccafferty, John Berdahl","doi":"10.2147/OPTH.S531475","DOIUrl":"10.2147/OPTH.S531475","url":null,"abstract":"<p><strong>Purpose: </strong>Enhanced understanding of intraocular pressure (IOP) dynamics by developing models improving upon foundational work in both steady-state and time-dependent domains.</p><p><strong>Methods: </strong>Two novel base equations are developed describing IOP dependent upon aqueous fluid flow into and out of the eye. The equations incorporate the parameters of fluid facility, venous and arteriolar pressures as well as initial and steady-state IOP. Basic validation was completed replicating existing glaucoma interventional studies. Equation 1 is a steady-state approximation of equilibrium between linear inflow and outflow facilities whose intercepts are the arteriolar intercept pressure and venous pressure, respectively. Equation 2 is a time-dependent approximation of IOP from an initial IOP also incorporating two or more inflow and outflow facilities as well as the steady-state solution.</p><p><strong>Results: </strong>The steady-state equation was validated by replicating the results of a published IOP efficacy study of combined netarsudil and latanoprost treatment results with a 3% error. The time-dependent equation was validated by replicating a published study examining mean time response of latanoprost IOP reduction to steady-state with an 8% error.</p><p><strong>Discussion: </strong>The combined steady-state and time-dependent IOP equations enable IOP equilibrium modeling incorporating inflow and outflow facility and the effects of arteriolar and venous pressures. Validation demonstrates applicability of the model with added interventional outflow and time-dependent IOP responses. Enhanced IOP equations provide a novel framework for modeling IOP dynamics. Potential applications include understanding IOP pathophysiology, evaluating therapeutic interventions, and predicting temporal/diurnal IOP fluctuations.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"2901-2911"},"PeriodicalIF":0.0,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12380090/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144982486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Maximum Tolerated Medical Therapy for Glaucoma: Fixed-Dose Combinations of Timolol, Dorzolamide, Brimonidine with Latanoprost Versus Timolol, Dorzolamide with Latanoprost. 青光眼的最大耐受药物治疗:替莫洛尔、多唑胺、溴莫尼定与拉坦前列素的固定剂量联合与替莫洛尔、多唑胺与拉坦前列素的联合
Clinical ophthalmology (Auckland, N.Z.) Pub Date : 2025-08-22 eCollection Date: 2025-01-01 DOI: 10.2147/OPTH.S540312
Oscar Olvera-Montaño, Claudia Mejia-Morales, Ricardo O Jauregui-Franco, Sandra Carolina Gomez-Mendez, Patricia Muñoz-Villegas
{"title":"Maximum Tolerated Medical Therapy for Glaucoma: Fixed-Dose Combinations of Timolol, Dorzolamide, Brimonidine with Latanoprost Versus Timolol, Dorzolamide with Latanoprost.","authors":"Oscar Olvera-Montaño, Claudia Mejia-Morales, Ricardo O Jauregui-Franco, Sandra Carolina Gomez-Mendez, Patricia Muñoz-Villegas","doi":"10.2147/OPTH.S540312","DOIUrl":"10.2147/OPTH.S540312","url":null,"abstract":"<p><strong>Purpose: </strong>Maximal medical therapy involves using three or more classes of topical anti-glaucoma agents to achieve the target intraocular pressure (IOP). This study compared the effectiveness, tolerability, and safety of a fixed combination of timolol, dorzolamide, brimonidine, and latanoprost (TDB-L) versus a fixed combination of timolol, dorzolamide, and latanoprost (TD-L) for uncontrolled IOP in patients with primary open-angle glaucoma.</p><p><strong>Methods: </strong>In this randomized, double-masked Phase IV trial, 47 eyes from 26 patients were assigned to TDB-Lor TD-L for 60 days, with follow-ups on days 14, 30, and 60. IOP was measured at 9:00 and 11:00 a.m. Follow-ups assessed tolerability via the Ocular Comfort Index (OCI) and conjunctival hyperemia (CH). Safety evaluations included chemosis, fluorescein conjunctival staining (FCS), visual acuity, corneal and retinal nerve fiber layer thickness, ganglion cell layer, and adverse events (AEs).</p><p><strong>Results: </strong>By day 60, both treatment groups achieved a significant reduction in IOP, with TDB-L decreasing from 20.1 ± 1.6 mmHg to 14.0 ± 2.2 mmHg and TD-L from 20.8 ± 1.8 mmHg to 16.8 ± 2.0 mmHg (between groups, p = 0.042). In the TDB-L group, the reduction in IOP by day 60 was 6.3 mmHg, compared to 4.5 mmHg in the TD-L group. OCI scores did not significantly change. By day 60, 15% of eyes exhibited moderate CH (all in TD-L, p = 0.002). The safety of both groups was similar, as neither presented drug-related AEs nor showed differences in safety parameters, with differences being found only in FCS (between groups, p = 0.001).</p><p><strong>Conclusion: </strong>Both TDB-L and TD-L achieved significant IOP reductions after two months, were well tolerated, and safe. Adding a fourth hypotensive agent may offer an effective option for patients needing more IOP reduction beyond TD-L, highlighting their role in managing glaucoma in regions with high socioeconomic burdens and limited treatment access.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov identifier NCT04702789, registered on 21 October 2019.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"2913-2925"},"PeriodicalIF":0.0,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12379996/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144982505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cyclodialysis Surgery for Glaucoma Management: A Systematic Review and Meta-Analysis of 100 Years of Clinical Evidence. 青光眼治疗的睫状体透析手术:100年临床证据的系统回顾和荟萃分析。
Clinical ophthalmology (Auckland, N.Z.) Pub Date : 2025-08-21 eCollection Date: 2025-01-01 DOI: 10.2147/OPTH.S538438
Robert Stamper, Alex Huang, Carol Toris, Mary Qiu, Gerry Gray, Reena Garg, Tsontcho Ianchulev
{"title":"Cyclodialysis Surgery for Glaucoma Management: A Systematic Review and Meta-Analysis of 100 Years of Clinical Evidence.","authors":"Robert Stamper, Alex Huang, Carol Toris, Mary Qiu, Gerry Gray, Reena Garg, Tsontcho Ianchulev","doi":"10.2147/OPTH.S538438","DOIUrl":"10.2147/OPTH.S538438","url":null,"abstract":"<p><strong>Synopsis: </strong>A meta-analysis of over 4000 glaucoma cases over 100 years of surgical experience demonstrates that cyclodialysis surgery is effective in lowering intraocular pressure (IOP) as an uveoscleral outflow enhancing procedure.</p><p><strong>Objective: </strong>To conduct a systematic review and meta-analysis evaluating the clinical efficacy and safety of surgical cyclodialysis in lowering intraocular pressure in glaucoma patients.</p><p><strong>Methods: </strong>A comprehensive search of PubMed, Cochrane, Web of Science, and EMBASE identified peer-reviewed interventional studies involving surgical cyclodialysis for IOP reduction. Key outcome measures included long-term IOP control, medication burden, and adverse event incidence. The meta-analysis was registered with PROSPERO (ID: CRD42025632759).</p><p><strong>Results: </strong>Forty studies spanning more than a century and including 4082 eyes were analyzed. Most studies were observational and non-randomized, with 75% employing ab-externo and 25% ab-key techniques. Given the evolution of surgical techniques and populations over time, analyses accounted for heterogeneity in outcome reporting. Across all studies, the average qualified success rate was 72.3% (range: 33-97%) over follow-up periods of 6 to 132 months. Ab-interno approaches showed slightly higher efficacy and fewer complications. Durability varied, with reduced outcomes in refractory and advanced glaucoma. Complications such as hyphema, hypotony, and vision loss were infrequent. Notably, newer ab-interno techniques demonstrated improved outcomes in IOP reduction, safety, and procedural longevity.</p><p><strong>Conclusion: </strong>Cyclodialysis remains a viable and effective surgical option for enhancing uveoscleral outflow in glaucoma management. While outcomes vary by patient severity and surgical technique, particularly with older methods, modern ab-interno approaches offer enhanced efficacy and safety-especially in mild to moderate cases.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"2859-2870"},"PeriodicalIF":0.0,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12377377/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144982544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Retrospective Data Analysis of Patients Treated with Difluprednate and Bromfenac for Cystoid Macular Edema After Uveitis or Cataract Surgery. 双氟泼尼酯和溴芬酸治疗葡萄膜炎或白内障手术后囊样黄斑水肿患者的回顾性资料分析
Clinical ophthalmology (Auckland, N.Z.) Pub Date : 2025-08-21 eCollection Date: 2025-01-01 DOI: 10.2147/OPTH.S516792
Nirmit Shah, Edward Tran, Sandra Caballero-Ortiz, Angela Kyveris, Toby Chan
{"title":"A Retrospective Data Analysis of Patients Treated with Difluprednate and Bromfenac for Cystoid Macular Edema After Uveitis or Cataract Surgery.","authors":"Nirmit Shah, Edward Tran, Sandra Caballero-Ortiz, Angela Kyveris, Toby Chan","doi":"10.2147/OPTH.S516792","DOIUrl":"10.2147/OPTH.S516792","url":null,"abstract":"<p><strong>Purpose: </strong>Cystoid macular edema (CME) is a condition which severely limits central vision, often occurring secondary to cataract surgery or uveitis. Although commonly treated with non-steroidal anti-inflammatory agents and a corticosteroid adjunct, an optimal medication regime has not yet been evaluated. Hence, we present a comprehensive analysis of the efficacy and relapse rate associated with various agents to treat CME, such as Bromfenac and Difluprednate.</p><p><strong>Patients and methods: </strong>A retrospective chart review was conducted on patients aged 18 and above diagnosed with postoperative or uveitic CME via optical coherence tomography from January 1, 2016, to December 31, 2023. Among these eligible patients, we investigated those treated with non-steroidal anti-inflammatory drugs (NSAIDs) and/or corticosteroids. The primary outcome was the duration until complete resolution of CME. Secondary outcomes included improvement of CME and the likelihood of CME recurrence after treatment. Statistical analysis involved ANOVA and Tukey's HSD test to compare treatment efficacy.</p><p><strong>Results: </strong>A total of 518 patients were analyzed. Difluprednate and bromfenac (n = 28) demonstrated the shortest mean resolution time (1.45 months) compared to other combinations. The ANOVA test revealed significant differences among treatment groups (F-value: 6.455, P-value: <0.00001), and Tukey's HSD test showed that difluprednate and bromfenac significantly outperformed other medications in treating cystoid macular edema (CME) by reducing resolution times by 5.40 months compared to ketorolac alone (P = 0.0011), 4.76 months compared to ketorolac and prednisolone acetate (P = 0.0001), 5.42 months compared to loteprednol and nepafenac (P < 0.0001), 5.40 months compared to dexamethasone and nepafenac (P < 0.0001), and 4.47 months compared to no treatment (P = 0.0240). Difluprednate and bromfenac also had no cases of CME recurrence.</p><p><strong>Conclusion: </strong>Difluprednate and bromfenac proved to be the most effective treatment regimen for cystoid macular edema (CME), resolving the condition in the shortest amount of time and requiring less frequent dosing.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"2879-2888"},"PeriodicalIF":0.0,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12377383/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144982399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Visual Performance and Subjective Outcomes with Enhanced Monofocal Intraocular Lens Implantation Targeted for Emmetropia or Modest Monovision. 增强单焦点人工晶状体植入术治疗斜视或中度单视的视觉表现和主观结果。
Clinical ophthalmology (Auckland, N.Z.) Pub Date : 2025-08-20 eCollection Date: 2025-01-01 DOI: 10.2147/OPTH.S533814
Tun Kuan Yeo, Don Chern Kuok Pek, John Xin Hao Wong
{"title":"Visual Performance and Subjective Outcomes with Enhanced Monofocal Intraocular Lens Implantation Targeted for Emmetropia or Modest Monovision.","authors":"Tun Kuan Yeo, Don Chern Kuok Pek, John Xin Hao Wong","doi":"10.2147/OPTH.S533814","DOIUrl":"10.2147/OPTH.S533814","url":null,"abstract":"<p><strong>Purpose: </strong>To determine the visual performance and patient reported outcomes after bilateral implantation of an enhanced monofocal intraocular lens (IOL) (RayOne EMV RAO200E) targeted for emmetropia or modest monovision.</p><p><strong>Patients and methods: </strong>This was a prospective, single-centre, comparative, interventional study. Patients were divided into two groups and targeted for bilateral emmetropia or modest monovision (-1.50 D in the near eye). Manifest refraction, monocular uncorrected and corrected distance visual acuity (UDVA and CDVA), uncorrected and distance-corrected intermediate visual acuity (UIVA and DCIVA), uncorrected and distance-corrected near visual acuity (UNVA and DCNVA), and monocular and binocular defocus curves under photopic and mesopic conditions were measured at 1-month post-surgery. The Catquest 9-SF questionnaire was administered to assess patient reported visual outcomes and quality of life.</p><p><strong>Results: </strong>60 patients were enrolled. For the emmetropia group (n = 30), the mean logMAR UDVA, UIVA and UNVA were 0.16±0.13, 0.35±0.12 and 0.50±0.15. In the monovision group (n = 30), the values for the distance eyes were 0.13±0.11, 0.40±0.11 and 0.56±0.13; and for the near eyes 0.41±0.21, 0.27±0.16 and 0.34±0.13. Binocular defocus curves showed similar distance visual acuity but better visual acuity in the monovision group from -1.00 D to -4.00 D and -1.00 D to -3.50 D defocus under photopic and mesopic conditions respectively (p < 0.05). The defocus range (logMAR 0.2 or better) was 1.3 D for the bilateral emmetropia group and 2.5 D for the monovision group. 90% (emmetropia group) and 96% (monovision group) of patients were very or fairly satisfied with their vision, with the monovision group reporting better performance for intermediate and near tasks.</p><p><strong>Conclusion: </strong>Patients targeted for bilateral emmetropia achieved good functional intermediate vision, while those with modest monovision experienced enhanced intermediate and near vision. Overall, patients reported high satisfaction and good visual performance when implanted with the enhanced monofocal IOL.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"2847-2857"},"PeriodicalIF":0.0,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12375324/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144982567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Jacques Daviel (1696-1762) and the Competition to Extract Cataracts: A Reappraisal. 雅克·戴维(1696-1762)和白内障摘除的竞争:重新评价。
Clinical ophthalmology (Auckland, N.Z.) Pub Date : 2025-08-20 eCollection Date: 2025-01-01 DOI: 10.2147/OPTH.S538655
Christopher Theodore Leffler, B Frits Hogewind, Stephen G Schwartz, Andrzej Grzybowski, Daniel M Albert
{"title":"Jacques Daviel (1696-1762) and the Competition to Extract Cataracts: A Reappraisal.","authors":"Christopher Theodore Leffler, B Frits Hogewind, Stephen G Schwartz, Andrzej Grzybowski, Daniel M Albert","doi":"10.2147/OPTH.S538655","DOIUrl":"10.2147/OPTH.S538655","url":null,"abstract":"<p><strong>Purpose: </strong>To analyze the timing and interactions among Jacques Daviel (1696-1762) and other Paris-based surgeons who pursued cataract extraction in the mid-18<sup>th</sup> century.</p><p><strong>Methods: </strong>Historical books, newspapers, and manuscripts were reviewed.</p><p><strong>Results: </strong>The claim of English oculist John Taylor that his visit to Daviel's hometown of Marseille in 1734 inspired Daviel to become an ophthalmologist is supported by contemporaneous evidence. In 1745, while in Marseille, Jacques Daviel switched from a single-instrument couching technique to a two-instrument technique. By September of 1748, while in Paris, Daviel had extracted remnants of a cataract from the posterior chamber following a failed couching. On July 1, 1750, a surgeon and monk named Jean Baseilhac (1703-1781), known as Frère Côme, was said to have performed cataract extraction through an incision in the center of the cornea. On July 3, 1750, in Paris, surgeon Natale Pallucci (1719-1797), made a corneal incision and extracted from the posterior chamber cataract fragments which remained after couching. For four months, beginning on July 7, 1750, in Leuven, Daviel experimented with planned cataract extraction in animals. On Sep. 18, 1750, in Cologne, Daviel performed a planned, primary cataract extraction on a cleric named Gilles Noupres.</p><p><strong>Conclusion: </strong>Jacques Daviel became an ophthalmologist in 1734 and secondarily extracted lens fragments by 1748. Three Paris-based eye surgeons, including Daviel, pursued the development of cataract extraction beginning in the first week of July 1750. The first contemporaneously documented planned cataract extraction through an incision was performed by Daviel in Cologne on Sep. 18, 1750.</p><p><strong>Summary: </strong>Three Paris-based surgeons, including Jacques Daviel, began to pursue cataract extraction in the first week of July 1750.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"2835-2846"},"PeriodicalIF":0.0,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12375357/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144982499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Practice Patterns and Technology Readiness for Sulcus Tube Placement: A Survey of the American Glaucoma Society Membership. 沟管置入的实践模式和技术准备:美国青光眼协会会员调查。
Clinical ophthalmology (Auckland, N.Z.) Pub Date : 2025-08-20 eCollection Date: 2025-01-01 DOI: 10.2147/OPTH.S532710
Anya Rahman, Jordan Whitney, Nadine Abdeljabbar, Aaron D Webel
{"title":"Practice Patterns and Technology Readiness for Sulcus Tube Placement: A Survey of the American Glaucoma Society Membership.","authors":"Anya Rahman, Jordan Whitney, Nadine Abdeljabbar, Aaron D Webel","doi":"10.2147/OPTH.S532710","DOIUrl":"10.2147/OPTH.S532710","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate glaucoma surgeons' practice patterns regarding glaucoma drainage device (GDD) tube shunt placement, assess their opinions on sulcus tube placement, and evaluate their receptiveness to technologies designed to improve sulcus tube placement.</p><p><strong>Patients and methods: </strong>A 12-question survey was distributed electronically to American Glaucoma Society (AGS) members between November 6 and December 23, 2024. The survey assessed surgeons' current tube-shunt placement practice patterns, factors influencing tube placement decisions, and receptiveness to proposed technologies designed for sulcus tube placement. Descriptive analysis was performed on 121 completed responses.</p><p><strong>Results: </strong>Most respondents (55%) reported a preference for placing tubes in the anterior chamber (AC) for the majority of their pseudophakic patients, with efficiency (62%), safety (62%), and familiarity (57%) reported as primary factors for this decision. Barriers to sulcus placement included concern for intraocular bleeding (67%), technical difficulty of sulcus placement (54%), the risk of vitreous loss and tube occlusion (53%), and iris complications (53%). However, if a sulcus tube insertion technology was available and assuming a randomized controlled trial (RCT) demonstrated the superiority of sulcus over AC placement in minimizing endothelial cell loss (ECL), 85% of respondents indicated they would be likely to routinely place tubes in the sulcus. Features deemed very important for such a technology included tube placement accuracy (87%), ease of use (86%), IOP-lowering effectiveness (73%), time-efficiency (71%), and affordability (67%).</p><p><strong>Conclusion: </strong>Currently, most glaucoma surgeons favor AC tube placement due to its familiarity, efficiency, and perceived safety, despite associated long-term risk of endothelial cell loss (ECL). Survey findings suggest strong interest in adopting sulcus placement, assuming a proven benefit on ECL and the availability of sulcus placement technologies designed to mitigate technical challenges. Development of robust data and reliable sulcus insertion technologies/techniques may change practice patterns.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"2871-2877"},"PeriodicalIF":0.0,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12375369/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144982503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Characteristics and Treatment Outcomes of Breakthrough Vitreous Hemorrhage in Peripheral Exudative Hemorrhagic Chorioretinopathy (PEHCR). 外周渗出出血性脉络膜视网膜病变(PEHCR)突破性玻璃体出血的临床特点及治疗效果。
Clinical ophthalmology (Auckland, N.Z.) Pub Date : 2025-08-19 eCollection Date: 2025-01-01 DOI: 10.2147/OPTH.S535257
Thanaporn Kritfuangfoo, Yanliang Li, William F Mieler
{"title":"Clinical Characteristics and Treatment Outcomes of Breakthrough Vitreous Hemorrhage in Peripheral Exudative Hemorrhagic Chorioretinopathy (PEHCR).","authors":"Thanaporn Kritfuangfoo, Yanliang Li, William F Mieler","doi":"10.2147/OPTH.S535257","DOIUrl":"10.2147/OPTH.S535257","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the clinical characteristics and treatment outcomes of breakthrough vitreous hemorrhage secondary to peripheral exudative hemorrhagic chorioretinopathy (PEHCR).</p><p><strong>Methods: </strong>This retrospective study included 14 eyes from 14 patients with vitreous hemorrhage secondary to peripheral retinochoroidal mass lesions. Data collected included demographic profiles, clinical presentation, multimodal imaging findings, and treatment outcomes following pars plana vitrectomy (PPV), intravitreal anti-VEGF injections, or laser photocoagulation.</p><p><strong>Results: </strong>The median age at presentation was 83 years (range, 58-91), with nine females (64.3%). Median presenting visual acuity (VA) was 1.3 logMAR (range, 0.3-2.7). All patients had normal intraocular pressure. Bilateral PEHCR was observed in 50%, though hemorrhage occurred unilaterally. Unifocal lesions were present in 71.4%, with a mean lesion thickness of 3.4 mm (range, 1.5-6.8 mm). Dense vitreous hemorrhage obscuring posterior pole details was seen in eight eyes (57.1%) and required PPV. The remaining six eyes, with moderate hemorrhage, improved spontaneously without surgery. Intravitreal anti-VEGF therapy was administered in five eyes for macular involvement or to prevent recurrent hemorrhage. At a median follow-up of 11.7 months (range, 3-63), median VA improved to 0.36 logMAR (range, 0.1-2.0). The mean VA gain was 0.76 logMAR in the vitrectomy group (p = 0.004) and 0.55 logMAR in eyes without macular involvement (p = 0.024). However, five eyes (35.7%) had final VA ≤ 20/200 due to macular pathology consistent with age-related macular degeneration or polypoidal choroidal vasculopathy-like changes.</p><p><strong>Conclusion: </strong>PEHCR with breakthrough vitreous hemorrhage is a rare but important diagnostic consideration in patients presenting with peripheral retinochoroidal mass-like lesions. PPV and intravitreal anti-VEGF therapy may improve visual outcomes in these cases. However, visual recovery may be limited in cases with macular involvement due to irreversible retinal damage. Early diagnosis and tailored management are essential to optimize outcomes and avoid misdiagnosis.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"2821-2833"},"PeriodicalIF":0.0,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12374697/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144982466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ophthalmic Changes in the Offspring of Pregnant Women with Gestational Diabetes Mellitus or Diabetes Mellitus - A Systematic Review. 妊娠期糖尿病或糖尿病孕妇后代视力变化的系统综述
Clinical ophthalmology (Auckland, N.Z.) Pub Date : 2025-08-18 eCollection Date: 2025-01-01 DOI: 10.2147/OPTH.S521323
Yushuai Liu, Jiashuang Yan, Mu Li, Dan Zhao
{"title":"Ophthalmic Changes in the Offspring of Pregnant Women with Gestational Diabetes Mellitus or Diabetes Mellitus - A Systematic Review.","authors":"Yushuai Liu, Jiashuang Yan, Mu Li, Dan Zhao","doi":"10.2147/OPTH.S521323","DOIUrl":"10.2147/OPTH.S521323","url":null,"abstract":"<p><strong>Background: </strong>Gestational diabetes mellitus (GDM) affects 5.8% to 25.1% of pregnant women and is associated with a range of adverse perinatal outcomes, including intrauterine growth restriction, prematurity, neonatal respiratory distress, and adiposity. Offspring of mothers with GDM or diabetes mellitus (DM) are also at elevated risk for long-term metabolic complications, such as obesity, dyslipidemia, and type 2 DM. While systemic and structural anomalies-including congenital heart disease, skeletal malformations, and renal agenesis-have been well documented, limited attention has been paid to ophthalmic consequences. Accordingly, this study aims to summarize current evidence on the impact of maternal GDM/DM on the ocular development and long-term visual outcomes in offspring.</p><p><strong>Methods: </strong>A review was conducted, integrating findings from studies describing ocular abnormalities in offspring born to mothers with GDM/DM.</p><p><strong>Results: </strong>GDM/DM during pregnancy may contribute to a spectrum of ocular anomalies in offspring, including hypoplasia of the iris stroma, vascular tortuosity and dilation of the iris vessels, optic nerve hypoplasia, decreased macular thickness and volume, and an increased risk of long-term ophthalmic morbidity such as refractive errors.</p><p><strong>Conclusion: </strong>Given the range of potential ophthalmic abnormalities in offspring of mothers with GDM/DM, regular ocular screening and long-term follow-up are recommended. Further research is warranted to better understand the underlying mechanisms and to develop evidence-based screening protocols.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"2803-2811"},"PeriodicalIF":0.0,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12372827/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144982497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信